Section I: The Economic Architecture of Pharmaceutical Patents The 20-Year Fiction: Why Statutory Term and Commercial Life Are Two Different […]
Drug Patent Prosecution: The Complete Strategic Playbook for Pharma IP Teams Read Post »
Who this is for: Pharma and biotech IP counsel, portfolio managers, R&D leads, generic drug strategy teams, business development executives,
Google Patents for Drug IP: The Free Tool That Creates Billion-Dollar Blind Spots Read Post »
A comprehensive framework covering due diligence, KPI architecture, IP asset valuation, technology roadmaps, and strategic governance across the full drug
When generic competition arrives, it arrives fast. Within the first 12 months of a major brand losing exclusivity, generic entrants
In-Licensing Branded Drugs: The Definitive IP Durability Playbook for Pharma Deal-Makers Read Post »
I. Executive Summary and Investment Thesis The Core Problem The generic drug industry saves the U.S. healthcare system roughly $216
Generic Drug Market: Why the Cheapest Medicine is Becoming the Most Expensive Problem Read Post »
Partnering with a Contract Development and Manufacturing Organization (CDMO) is no longer a simple procurement exercise. It is a fundamental
CDMO Selection: The Ultimate Checklist Read Post »
1. Executive Summary and Key Takeaways The FDA’s Product-Specific Guidance (PSG) program is now the most consequential publicly available dataset
FDA Product-Specific Guidances: The Generic Drug Trigger Every Portfolio Manager Needs Read Post »
The complete 2025 playbook for generic drug development strategy: Paragraph IV mechanics, complex generics IP moats, biosimilar development roadmaps, IRA
Stop Chasing Patent Cliffs. Build a Portfolio That Wins After Them. Read Post »
The global pharmaceutical landscape is undergoing a tectonic shift, and at its epicenter lies India. Long celebrated as the “Pharmacy
India’s Growing Importance in Generic Drug API Manufacturing Read Post »
Sign in or create a free account to read this DrugPatentWatch article
